多组学整合分析揭示肝细胞癌全面肿瘤异质性及新型免疫表型分类
研究采集8例肝细胞癌患者的42份样本,整合全外显子组、转录组、蛋白质组、代谢组及单细胞分析,发现肿瘤在基因组、转录组、蛋白质组和代谢组层面异质性显著,而免疫微环境异质性较低。基于免疫细胞聚类提出免疫健全、免疫缺陷和免疫抑制三种亚型,并用CD45和Foxp3免疫组化辅助分类与预后预测。
要点
- 肝细胞癌在基因组、转录组、蛋白质组和代谢组层面均存在显著瘤内和瘤间异质性。
- 免疫微环境异质性相对较低,靶向局部免疫可能是兼顾精准与可行的干预方向。
- 基于免疫细胞聚类可区分免疫健全、免疫缺陷和免疫抑制三种亚型,CD45和Foxp3免疫组化有助于分类和预后预测。
核心结论
- 肝细胞癌在所有维度均存在全面的瘤内和瘤间异质性。
- 基于免疫细胞聚类提出的新型免疫表型分类有助于预后预测,并可能支持治疗选择决策。
研究设计与样本
- 采集8例肝细胞癌患者的42份样本,采用全外显子组测序、RNA测序、质谱蛋白质组学和代谢组学、飞行时间流式细胞术及单细胞分析进行评估。
- 用免疫组化和定量聚合酶链反应确认基因表达水平,并用三个独立队列验证发现。
主要发现
- 病灶和肿瘤在基因组、转录组、蛋白质组和代谢组层面异质性显著。
- 肝细胞癌微环境免疫状态异质性相对较低。
- 通过免疫细胞聚类识别出免疫健全、免疫缺陷和免疫抑制三种特征性亚型。
- 揭示了不同亚型特异的代谢特征及细胞因子/趋化因子表达水平。
- 用免疫组化检测CD45和Foxp3表达有助于正确分类肝细胞癌患者并预测其预后。
关键数值与推荐
- 根据免疫细胞聚类将肝细胞癌分为免疫健全、免疫缺陷和免疫抑制三种亚型。
- CD45和Foxp3免疫组化用于辅助肝细胞癌患者分类和预后预测。
临床怎么用
- 靶向局部免疫可能是兼顾精准度和可行性的干预方向。
- 基于免疫表型分类可能支持治疗选择决策。
- CD45和Foxp3免疫组化可用于辅助肝细胞癌患者分类和预后预测。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hepatocellular carcinoma (HCC) is heterogeneous, especially in multifocal tumours, which decreases the efficacy of clinical treatments. Understanding tumour heterogeneity is critical when developing novel treatment strategies. However, a comprehensive investigation of tumour heterogeneity in HCC is lacking, and the available evidence regarding tumour heterogeneity has not led to improvements in clinical practice. DESIGN: We harvested 42 samples from eight HCC patients and evaluated tumour heterogeneity using whole-exome sequencing, RNA sequencing, mass spectrometry-based proteomics and metabolomics, cytometry by time-of-flight, and single-cell analysis. Immunohistochemistry and quantitative polymerase chain reactions were performed to confirm the expression levels of genes. Three independent cohorts were further used to validate the findings. RESULTS: Tumour heterogeneity is considerable with regard to the genomes, transcriptomes, proteomes, and metabolomes of lesions and tumours. The immune status of the HCC microenvironment was relatively less heterogenous. Targeting local immunity could be a suitable intervention with balanced precision and practicability. By clustering immune cells in the HCC microenvironment, we identified three distinctive HCC subtypes with immunocompetent, immunodeficient, and immunosuppressive features. We further revealed the specific metabolic features and cytokine/chemokine expression levels of the different subtypes. Determining the expression levels of CD45 and Foxp3 using immunohistochemistry facilitated the correct classification of HCC patients and the prediction of their prognosis. CONCLUSION: There is comprehensive intratumoral and intertumoral heterogeneity in all dimensions of HCC. Based on the results, we propose a novel immunophenotypic classification of HCCs that facilitates prognostic prediction and may support decision making with regard to the choice of therapy.
引用
- Zhang Q, Lou Y, Yang J, et al. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut. 2019. PMID: 31227589. doi:10.1136/gutjnl-2019-318912
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。